Heterocyclic GLP-1 agonists

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published April 7th, 2026

Detected April 7th, 2026

Summary

USPTO granted patent US12595264B2 to Gasherbrum Bio, Inc. on April 7, 2026, covering heterocyclic GLP-1 receptor agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent names six inventors and contains 24 claims, with CPC classifications spanning heterocyclic chemistry (C07D 487/04), phosphorus compounds (C07F 9/6561), and pharmaceutical formulations (A61K 31/4985, A61K 38/26).

View original document View source feed page

What changed

USPTO issued patent US12595264B2 to Gasherbrum Bio, Inc. for heterocyclic GLP-1 agonists of Formula (I), including pharmaceutical salts, solvates, and compositions. The patent covers 24 claims across heterocyclic chemistry, phosphorus compounds, and pharmaceutical formulations related to GLP-1 receptor modulation.

Pharmaceutical and biotechnology companies developing GLP-1 based therapies for diabetes, obesity, or metabolic disorders should monitor this patent landscape when designing R&D programs, formulation strategies, and licensing arrangements to avoid infringement on Gasherbrum Bio's newly granted IP rights.

What to do next

Monitor for updates

Source document (simplified)

← USPTO Patent Grants

Heterocyclic GLP-1 agonists

Grant US12595264B2 Kind: B2 Apr 07, 2026

Assignee

Gasherbrum Bio, Inc.

Inventors

Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings

Abstract

This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.